title: Oligodendroglial tumors.
abstract: Oligodendroglial tumors represent approximately 4-7% of all gliomas; however, in some series the incidence has been reported to be as high as 10-20% because of improved histological appreciation and recently recognized molecular signatures. Oligodendroglial tumors are classified as being low-grade oligodendroglial tumors, high-grade anaplastic oligodendroglial tumors or mixed oligo-astrocytic tumors. The mixed tumors can again be low-grade or high-grade. The recent European Organization for Research and Treatment of Cancer and Radiation Therapy Oncology Group randomized trials have provided level 1 evidence regarding the best management of these tumors. This review provides an overview of oligodendroglial tumors and discusses contemporary and evolving treatment strategies.
authors.affiliation: H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33611, USA. chambemc@moffitt.usf.edu
authors.forename: Sajeel
authors.initials: S
authors.lastname: Chowdhary
authors.forename: Marc C
authors.initials: MC
authors.lastname: Chamberlain
mesh_terms: D001932:Brain Neoplasms / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D009837:Oligodendroglioma / Q000145:classification / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*